# M.D. Anderson Cancer Center: Phase 2 study completed, 38 enrolled (Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | M.D. Anderson Cancer Center |
| Sponsor type | Academic and hospital |
| Study | Study of Pembrolizumab (MK-3475) in Combination With Romidepsin |
| NCT ID | NCT03278782 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Anaplastic Large Cell Lymphoma |
| Intervention types | biological, drug |
| Target enrollment | 38 |
| Site countries | United States |
| Posted | 2017-09-12 |
| Planned start | 2017-11-14 |
| Event | Completed |
| Event date | 2026-10-09 |
| Last update posted | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03278782). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.